Sana Biotechnology

FDA grants Fast Track designation to Sana Biotechnology's SC291 for relapsed/refractory systemic lupus erythematosus. SC291, a hypoimmune CD19-directed allogeneic CAR T therapy, is being evaluated in the GLEAM trial for B-cell mediated autoimmune diseases, with initial data expected in 2025.

Sana Biotechnology announced FDA Fast-track Designation for SC91 in treating R/R systemic lupus erythematosus. SC91, a HIP-modified CD19-directed allogeneic CAR T therapy, is evaluated in the GLEAM trial for B-cell mediated autoimmune diseases. The Phase 1 study assesses SC91's safety and benefits, with initial data expected in 2025.

Sana Biotechnology granted fast track designation for SC291, a CD19-directed allogeneic CAR T cell therapy for relapsed and refractory systemic lupus erythematosus. The therapy is being evaluated in a trial for B-cell mediated autoimmune diseases, with initial data expected in 2025.

FDA grants Fast Track designation for SC291, Sana Biotechnology's hypoimmune CD19-directed allogeneic CAR T therapy for relapsed/refractory systemic lupus erythematosus (SLE). Enrolling patients in GLEAM trial for B-cell mediated autoimmune diseases, expecting initial data in 2025.

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of scraping tools. Account usually reactivates within 24 hours; contact support if still disabled.

Sana Biotechnology announced FDA Fast Track designation for SC291, an allogeneic CAR T therapy for relapsed/refractory systemic lupus erythematosus (SLE). The GLEAM trial, evaluating SC291 in B-cell mediated autoimmune diseases, is enrolling patients with initial data expected in 2025. SC291's scalable manufacturing can produce hundreds of doses per run, positioning it as a potential universal off-the-shelf therapy.

Sana Biotechnology received FDA Fast Track designation for SC291, a HIP-modified CD19-directed allogeneic CAR T therapy, targeting relapsed/refractory systemic lupus erythematosus. Enrolling patients in the GLEAM trial, initial data expected in 2025. SC291 aims to serve as a universal off-the-shelf therapy for B-cell mediated autoimmune diseases.

Sana Biotechnology stock rose 9.8% to $2.80, with 608,151 shares traded, down 71% from average volume. Analysts' price targets varied, with Citigroup raising theirs from $8.00 to $15.00, while JMP Securities downgraded the stock. Director Richard Mulligan sold 150,000 shares at $4.08 each, reducing his stake by 5.00%.

DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.